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Background: There is scarce data on interventional outcomes in octogenarians. Drug-eluting stents (DES) should be advantageous over bare 
metal stent (BMS) in reducing restenosis but a higher toleration for restenosis could decrease effectiveness. The potential downside of DES is the 
prolonged course of dual antiplatelet therapy.
methods: We designed a multicentre randomised trial of Xience DES and Vision BMS in octogenarians. Patients with STEMI were excluded. Primary 
outcome was the combined of death, infarction, TVR, stroke and major bleeding (TIMI) at one year. Estimated sample size was 329 patients in each 
group.
results: 800 patients were recruited in 22 centres across the UK and Spain. The patients were well matched between the 2 groups with only 
significant differences in prior infarction (21.5% in BMS group and 29.8% in DES group) and total stent length (24±13 mm with BMS and 26±14 
mm with DES). A 68% of patients were treated after and ACS. Recommended DAPT period was 1 month after BMS and 12 months after DES. One year 
outcomes for both groups are shown in the table. In subgroup analysis DES was more beneficial in males, 85-90 yrs, stable angina, 2-vessel disease 
and radial access.
conclusions: This trial evaluating DES and BMS in octogenarians has shown at 1 year no difference in mortality between groups, similar rates of 
major haemorrhage despite differing DAPT regimes and significantly lower rates of target vessel revascularization and myocardial infarction among 
DES-treated patients.
Clinical outcomes
Vision (BMS)
N=401
Xience (DES)
N=399
p
Death 7.2% 8.5% 0.5
Infarction 8.7% 4.3% 0.01
TVR 7% 2% 0.0009
Major bleeding 1.7% 2.3% 0.6
Stroke 1.2% 1.5% 0.7
Primary endpoint 18.7% 14.5% 0.09
